GlassScriptPhysician profile
Hardeep Singh Phull
NPI 1306103510
$338,581.25
in general payments reported to CMS, 2019-2025
24 companies · $77K in 2025
The $77K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,117 · 2020: $16K · 2021: $27K · 2022: $97K · 2023: $75K · 2024: $40K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $42K · Honoraria: $40K · Travel and Lodging: $14K · Consulting Fee: $9,100 · Food and Beverage: $3,868 · Education: $9.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,155.38 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $42,035.00 |
| Honoraria | $39,935.00 |
| Travel and Lodging | $13,992.84 |
| Consulting Fee | $9,100.00 |
| Food and Beverage | $3,867.54 |
| Education | $9.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $134,595.34 | 2021-2025 | Fotivda |
| Genzyme Corporation | $95,477.63 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $92,039.20 | 2021-2025 | Xpovio |
| Mirati Therapeutics, INC. | $11,660.99 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $3,048.07 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $433.77 | 2019-2025 | Opdivo, Opdualag |
| Amgen INC. | $239.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $135.39 | 2022-2025 | |
| Tempus Ai, INC | $127.54 | 2024-2025 | Xt Cdx |
| Syndax Pharmaceuticals, INC. | $121.36 | 2025 | Revuforj |
| Glaxosmithkline, LLC. | $121.11 | 2021 | |
| Epizyme, INC. | $119.01 | 2021 | |
| Daiichi Sankyo INC. | $86.75 | 2022-2025 | Enhertu |
| Pfizer INC. | $86.17 | 2019-2025 | |
| Stemline Therapeutics INC. | $86.01 | 2023 | Orserdu |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $31.47 | 2022 | |
| Abbvie INC. | $27.61 | 2025 | |
| Kite Pharma, INC. | $24.92 | 2024 | Yescarta |
| Abbott Laboratories | $24.21 | 2022 | |
| Myriad Genetic Laboratories, INC. | $22.18 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.49 | 2020 | |
| Merck Sharp & Dohme LLC | $19.53 | 2020 | |
| Seagen INC. | $17.13 | 2022 | |
| Gilead Sciences, INC. | $14.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hardeep Phull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.